Travere Therapeutics (TVTX) Total Non-Current Liabilities (2011 - 2026)

Travere Therapeutics has reported Total Non-Current Liabilities for 16 years, with the latest figure at $447.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 12.11% year-over-year to $447.1 million; the trailing twelve-month figure through Mar 2026 stood at $447.1 million (down 12.11% YoY), and the FY2025 full-year result was $482.8 million, down 8.61% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $447.1 million, down from $482.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $620.3 million in Q4 2022, with the low at $447.1 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $546.4 million across 5 years, with a median of $544.7 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 70.28% — and 2024, when it fell 15.03%.
• Travere Therapeutics' Total Non-Current Liabilities stood at $620.3 million in 2022, then fell by 6.86% to $577.8 million in 2023, then slipped by 8.57% to $528.3 million in 2024, then slipped by 8.61% to $482.8 million in 2025, then decreased by 7.39% to $447.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $447.1 million (Q1 2026), $482.8 million (Q4 2025), and $459.1 million (Q3 2025), per Business Quant data.